Copyright: ©Author(s) 2026.
World J Clin Cases. Aug 26, 2026; 14(24): 123303
Published online Aug 26, 2026. doi: 10.12998/wjcc.123303
Published online Aug 26, 2026. doi: 10.12998/wjcc.123303
Figure 3 Clinical timeline.
March 2025 [admission, multidisciplinary team (MDT)] → April 2, 2025 (percutaneous transhepatic cholangial drainage) → April 14, 2025 (laparoscopic pancreaticoduodenectomy) → postoperative pathology (large cell neuroendocrine carcinoma, proficient mismatch repair, R1) → MDT discussion [exclusion of immunotherapy, selection of etoposide plus (EP) regimen] → May–August 2025 (EP × 6 cycles) → September 2025 (negative computed tomography) → April 2026 (last follow-up, disease-free survival). MDT: Multidisciplinary team; PTCD: Percutaneous transhepatic cholangial drainage; LPD: Laparoscopic pancreaticoduodenectomy; EP: Etoposide plus cisplatin; LCNEC: Large cell neuroendocrine carcinoma.
- Citation: Zheng BQ, Wang ZP, Feng RZ, Zheng ZC, Wang HJ, Wang H, Tuo HF. Large cell neuroendocrine carcinoma of the distal common bile duct: A case report and literature review. World J Clin Cases 2026; 14(24): 123303
- URL: https://www.wjgnet.com/2307-8960/full/v14/i24/123303.htm
- DOI: https://dx.doi.org/10.12998/wjcc.123303